Acute Spinal Cord Injury Market Report 2026

The acute spinal cord injury market size has grown strongly in recent years. It will grow from $7.06 billion in 2025 to $7.43 billion in 2026 at a compound annual growth rate (CAGR) of 5.2%. The growth in the historic period can be attributed to increasing incidence of traumatic spinal injuries, expansion of hospital and trauma care facilities, rising awareness of acute sci treatment, adoption of advanced imaging technologies, government initiatives for spinal injury management.

The acute spinal cord injury market size is expected to see strong growth in the next few years. It will grow to $9.4 billion in 2030 at a compound annual growth rate (CAGR) of 6.1%. The growth in the forecast period can be attributed to development of neuroregenerative therapies, growth in rehabilitation centers and specialized clinics, increasing research funding for spinal cord repair, rising integration of ai in diagnostics, expansion of personalized treatment approaches. Major trends in the forecast period include advancements in spinal cord injury diagnostic imaging, rising adoption of minimally invasive surgical techniques, increased focus on rehabilitation and physiotherapy solutions, growing investment in acute sci research and clinical trials, enhanced development of neuroprotective and regenerative therapies.

Increasing numbers of road accidents are expected to drive the growth of the acute spinal cord injury market going forward. A road accident is an incident involving the collision of a motor vehicle that results in injury or fatality. Accidental spinal injuries can damage the central nervous system (CNS) and disrupt nerve pathways required for motor and sensory functions. The severity of an accident can cause trauma to the cervical, lumbar, or thoracic spine, potentially damaging or severing the spinal cord and leading to paralysis. For instance, in June 2024, according to the Llywodraeth Cymru / Welsh Government, a Wales-based government administration, police forces in Wales reported 4,348 road casualties in 2023, representing a 2% increase compared to 2022. Therefore, the rise in road accidents is fueling the growth of the acute spinal cord injury market.

Major companies operating in the acute spinal cord injury market are focusing on developing advanced therapies, such as mesenchymal stem cell-derived exosomes loaded with siRNA, to support neural regeneration, reduce cell death, and promote axonal regrowth. Mesenchymal stem cell-derived exosomes are small extracellular vesicles released by mesenchymal stem cells that carry proteins, lipids, and RNA molecules, facilitating cell-to-cell communication while promoting tissue repair, regeneration, and immune modulation. For instance, in May 2025, NurExone Biologic Inc., a Canada-based pharmaceutical technology company, announced plans to initiate a Phase 1/2a clinical trial in 2026 for ExoPTEN, a therapy designed for adult patients with traumatic spinal cord injury treated within 3 to 7 days post-injury. The therapy uses intranasal and intrathecal delivery to reach the injury site and has shown strong recovery of motor, sensory, and structural function in preclinical models, with fluorescent labeling confirming its ability to home to the injury site for up to seven days, highlighting its potential as a minimally invasive regenerative treatment.

In February 2023, Globus Medical Inc., a US-based developer and manufacturer of musculoskeletal device solutions, acquired NuVasive Inc. for $3.1 billion. This acquisition strengthened Globus Medical’s portfolio in musculoskeletal disorder devices, reinforcing its position as a leading musculoskeletal technology company. NuVasive Inc. is a US-based developer of medical devices and procedures for minimally invasive spinal cord surgery.

Major companies operating in the acute spinal cord injury market are Pfizer Inc, AbbVie Inc., Biogen Inc., Mitsubishi Tanabe Pharma Corporation, BioMarin Pharmaceutical Inc., Neuralstem Inc., Acorda Therapeutics Inc., Omeros Corporation, Lineage Cell Therapeutics Inc., Pharmazz Inc., Asterias Biotherapeutics Inc., Histocell S.L., Athersys Inc., ReNetX Bio, Kringle Pharma Inc., BioArctic AB, BioAxone BioSciences Inc., InVivo Therapeutics Holdings Corp, Geron Corporation, Neuronax SA.

North America was the largest region in the acute spinal cord injury market in 2025. The regions covered in the acute spinal cord injury market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the acute spinal cord injury market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have influenced the acute spinal cord injury market by increasing the cost of imported imaging equipment, surgical tools, and rehabilitation devices. Diagnostic and surgical segments are particularly impacted, with north america, europe, and asia-pacific regions facing elevated procurement costs. These tariffs have caused delays and higher treatment expenses but have also encouraged domestic manufacturing of medical equipment, innovation in cost-effective rehabilitation solutions, and greater regional supply chain resilience.

The acute spinal cord injury market research report is one of a series of new reports that provides acute spinal cord injury market statistics, including acute spinal cord injury industry global market size, regional shares, competitors with a acute spinal cord injury market share, detailed acute spinal cord injury market segments, market trends and opportunities, and any further data you may need to thrive in the acute spinal cord injury industry. This acute spinal cord injury market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Acute spinal cord injury (SCI) is a traumatic condition that can result in a bruise (contusion), a partial tear, or a complete tear (transection) of the spinal cord. This injury can cause a reduction or loss of movement, sensation, and organ function below the level of the injury. Acute spinal cord injuries are more prevalent in men and young adults and can result from factors such as motor vehicle accidents, falls, sports injuries, and surgical complications.

The main types of acute spinal cord injuries are complete spinal cord injury and incomplete spinal cord injury. Complete spinal cord injury involves a total loss of sensory and motor function below the level of the spinal cord injury. Diagnosis is carried out through laboratory tests and imaging tests, typically in hospitals and clinics.

The acute spinal cord injury market include revenues earned through entities by types such as complete spinal cord injury and incomplete spinal cord injury. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.